-
Novartis announces phase III NATALEE trial of Kisqali reduces risk of recurrence in younger patients with early breast cancer
03 Jun 2025 12:31 GMT
… of recurrence and fewer treatment discontinuations due to adverse … anastrozole or letrozole) and goserelin if applicable. The primary … from China’s National Medical Products Administration. In MBC … across three phase III trials. The NCCN Guidelines also …
-
AstraZeneca & Daiichi Sankyo announce positive results from DESTINY-Breast09 phase III trial of Enhertu plus pertuzumab to treat HER2-positive metastatic breast cancer
03 Jun 2025 08:43 GMT
… DESTINY-Breast09 phase III trial showed Enhertu (trastuzumab … was stratified by prior treatment (de novo metastatic disease … 47;or DESTINY-Gastric06 trials. Continued approval in … with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
02 Jun 2025 12:21 GMT
… DESTINY-Breast09 Phase III trial showed ENHERTU® (fam … 47;or DESTINY-Lung05 trials. Continued approval in China … outcomes with foundational medicines fulvestrant and goserelin and aims to … Breast Cancer: Patient Characteristics, Treatment, and Survival from the …
-
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
01 Jun 2025 12:10 GMT
… free survival (PFS). The trial evaluated switching to the camizestrant … how we think about drug resistance in this type … in Phase III trials for the treatment of HR-positive … outcomes with foundational medicines fulvestrant and goserelin and aims to …
-
Enhertu followed by THP before surgery showed statistically significant and clinically meaningful improvement in pCR in patients with high─risk HER2─positive early─stage breast cancer in DESTINY─Breast11 phase III trial
08 May 2025 07:10 GMT
… complete response with treatment in the neoadjuvant setting … HER2-directed DXd antibody drug conjugate (ADC) discovered … trials including the DESTINY-Breast05 phase III trial … with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and …
-
October - December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
31 Mar 2025 19:52 GMT
… one or more antidepressant(s)
Discontinuation-emergent cataplexy
FDA is evaluating the … )
Zoladex (goserelin implant)
Suicidal and self-injurious behaviors
FDA is evaluating … information about hepatotoxicity.
An FDA Drug Safety Communication was issued on …
-
'Transformational' pill for endometriosis gets NHS nod
13 Mar 2025 22:44 GMT
… after initially turning down the drug in earlier draft guidance.
The … endometriosis patients for whom medical or surgical treatment has failed.
NICE… ) and AstraZeneca's Zoladex (goserelin acetate) – which are only licensed …
-
Gedeon Richter’s once-daily endometriosis pill approved for NHS use
14 Mar 2025 09:30 GMT
… Service (NHS).
The drug works by blocking gonadotrophin … and AstraZeneca’s Zoladex (goserelin) – which are limited to … medicines evaluation at NICE, highlighted the benefits of a pill-based treatment … the parent company of Pharmaceutical Technology.
Sign up …
-
The Role of Medications in Modern Cancer Treatment
04 Mar 2025 08:08 GMT
… research and new medication options. Developing pharmaceutical treatments is a cornerstone … include leuprolide, goserelin and triptorelin. Surgical or medical castration to eliminate … strategy.
Off-Label Drug Uses
Sometimes drugs approved for other uses …
-
AstraZeneca announces positive results from SERENA─6 phase III trial of camizestrant in combo with CDK 4/6 inhibitor to treat 1st─line advanced HR─positive breast cancer
27 Feb 2025 05:00 GMT
… progression-free survival (PFS). The trial evaluated switching to the camizestrant … currently in Phase III trials for the treatment of HR-positive breast … improve outcomes with foundational medicines Faslodex and Zoladex (goserelin) and aims to …
About
© 1995-2025